These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 2567957

  • 1. [Nizatidine].
    Romero M, Franzosi MG.
    Medicina (Firenze); 1989; 9(1):93-6. PubMed ID: 2567957
    [Abstract] [Full Text] [Related]

  • 2. A comparison of nizatidine with the three other histamine receptor antagonists for duodenal ulcer therapy.
    Lima M, Holdcroft C.
    Nurse Pract; 1989 Feb; 14(2):41-2. PubMed ID: 2564655
    [Abstract] [Full Text] [Related]

  • 3. Clinical review of histamine2 receptor antagonists.
    Lipsy RJ, Fennerty B, Fagan TC.
    Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
    [Abstract] [Full Text] [Related]

  • 4. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Price AH, Brogden RN.
    Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
    [Abstract] [Full Text] [Related]

  • 5. Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration.
    Pace F, Colombo E, Ferrara A, Prada A, Rocca F, Bianchi Porro G.
    Am J Gastroenterol; 1988 Jun; 83(6):643-5. PubMed ID: 2897784
    [Abstract] [Full Text] [Related]

  • 6. The effect of an oral morning dose of nizatidine and ranitidine on gastric acid secretion in duodenal ulcer patients.
    Lazzaroni M, Bianchi Porro G.
    Hepatogastroenterology; 1989 Dec; 36(6):490-3. PubMed ID: 2575571
    [Abstract] [Full Text] [Related]

  • 7. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
    Kuipers EJ, Hazenberg HJ, Quik RF, Hazenberg BP, de Zwart PA.
    Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of acute stomach ulcer with H2 receptor antagonists. A direct therapy comparison with 300 mg nizatidine nightly and 2 times 150 mg nizatidine with twice daily 150 mg ranitidine].
    Arnold R, Beckenbach P, Bock H, Bormann R, Brunner G, Daake H, Dammann HG, Dietrich K, Fuerer M, Geiter B.
    Fortschr Med; 1989 Jun 10; 107(17):390-4. PubMed ID: 2568327
    [Abstract] [Full Text] [Related]

  • 9. Famotidine. The ACG Committee on FDA-Related Matters with primary authorship by G. Friedman. American College of Gastroenterology.
    Am J Gastroenterol; 1987 Jun 10; 82(6):504-6. PubMed ID: 2883885
    [Abstract] [Full Text] [Related]

  • 10. Nizatidine: a new histamine receptor blocker in the treatment of active duodenal ulcers.
    Levendoglu H, Mehta B, Wait C, Reddy G, Hatcher C.
    Am J Gastroenterol; 1986 Dec 10; 81(12):1167-70. PubMed ID: 2878607
    [Abstract] [Full Text] [Related]

  • 11. Nizatidine in the short-term treatment of duodenal ulcer--an Italian Multicenter Study.
    Bovero E, Poletti M, Boero A, Mura BC, Camarri E, Corradini P, Corsini G, Federici G, Curzio M, Gianquinto G.
    Hepatogastroenterology; 1987 Dec 10; 34(6):269-71. PubMed ID: 2892768
    [Abstract] [Full Text] [Related]

  • 12. Histamine H2-receptor antagonists.
    Pounder R.
    Baillieres Clin Gastroenterol; 1988 Jul 10; 2(3):593-608. PubMed ID: 2901868
    [Abstract] [Full Text] [Related]

  • 13. Famotidine in the USA: a review of efficacy studies.
    Gitnick G.
    J Int Med Res; 1989 Jul 10; 17 Suppl 1():17A-24A. PubMed ID: 2566539
    [Abstract] [Full Text] [Related]

  • 14. Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study.
    Di Mario F, Battaglia G, Naccarato R, D'Angelo A, Saggioro A, Da Broi GL, Vezzadini P, Bianchi Porro G.
    Hepatogastroenterology; 1990 Dec 10; 37 Suppl 2():62-5. PubMed ID: 1982108
    [Abstract] [Full Text] [Related]

  • 15. [The effects of nizatidine and misoprostol on peptic activity and gastric mucus].
    Grassi SA, Vianello F, Germanà B, Dal Santo P, Faggian D, Battaglia G, Plebani M, Di Mario F, Naccarato R.
    Medicina (Firenze); 1990 Dec 10; 10(1):29-31. PubMed ID: 1974318
    [Abstract] [Full Text] [Related]

  • 16. [Effects of nizatidine, a new histamine H2-receptor antagonist, on gastric acid secretion and various gastric and duodenal lesions in rats: comparison with cimetidine].
    Okabe S, Takeuchi K, Okada M, Kumadaki Y, Nakata M, Nakata H.
    Nihon Yakurigaku Zasshi; 1989 Mar 10; 93(3):133-44. PubMed ID: 2567267
    [Abstract] [Full Text] [Related]

  • 17. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients.
    Savarino V, Mela GS, Zentilin P, Sumberaz A, Bonifacino G, Celle G.
    Am J Gastroenterol; 1991 Mar 10; 86(3):281-4. PubMed ID: 1671805
    [Abstract] [Full Text] [Related]

  • 18. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
    Dammann HG, Gottlieb WR, Walter TA, Dreyer M, Müller P, Simon B, Keohane P.
    Hepatogastroenterology; 1986 Oct 10; 33(5):217-20. PubMed ID: 2879782
    [Abstract] [Full Text] [Related]

  • 19. [Nizatidine versus ranitidine in the treatment of acute duodenal ulcer. Comparison of 300 mg nizatidine and 300 mg ranitidine in a single evening dose].
    Arnold R, Beckenbach P, Bock H, Bormann R, Daake H, Dammann HG, Du Bosque G, Fürer M, Geiter B, Hebbeln H.
    Fortschr Med; 1989 Jul 20; 107(21):467-70. PubMed ID: 2570012
    [Abstract] [Full Text] [Related]

  • 20. Fourth histamine antagonist, nizatidine, reaches U.S. market.
    Clin Pharm; 1988 Aug 20; 7(8):560. PubMed ID: 2901936
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.